PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses precision method for patient selection ...

In a recent study published in the Proceedings of the National Academy of Sciences Journal, researchers examined the therapeutic effects of targeting integrins for treating Amyotrophic lateral ...

Integrin α-4/β-7 - also known as Lymphocyte Peyer’s patch adhesion molecule-1 (LPAM-1) - is an integrin heterodimer composed of covalently linked α-4 and β-7 subunits. Expressed on the surface of ...

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and ...

WALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...

Researchers at the University of California, San Diego (UCSD) School of Medicine have developed a mouse model that could help scientists develop better drugs to fight autoimmune and inflammatory ...

WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...